Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
In Vitro Antifungal Susceptibility Profile of Iranian Fusarium Isolates: Emphasising on the Potent Inhibitory Effect of Efinaconazole Compared to Other Drugs Publisher Pubmed



Nosratabadi M1, 2 ; Faeli L1, 2 ; Haghani I1, 2 ; Mohammadi R3 ; Khodavaisy S4 ; Kachuei R5 ; Katiraee F6 ; Aghili SR1, 2 ; Shokohi T1, 2 ; Hedayati MT1, 2 ; Nazeri M7 ; Javannikkhah M8 ; Zarrinfar H9 ; Javidnia J1, 2 Show All Authors
Authors
  1. Nosratabadi M1, 2
  2. Faeli L1, 2
  3. Haghani I1, 2
  4. Mohammadi R3
  5. Khodavaisy S4
  6. Kachuei R5
  7. Katiraee F6
  8. Aghili SR1, 2
  9. Shokohi T1, 2
  10. Hedayati MT1, 2
  11. Nazeri M7
  12. Javannikkhah M8
  13. Zarrinfar H9
  14. Javidnia J1, 2
  15. Najafzadeh MJ10
  16. Salimi M1, 2
  17. Ms Al Hatmi A11, 12
  18. Badali H13
  19. Abastabar M1, 2

Source: Mycoses Published:2023


Abstract

Background: Fusarium species are opportunistic human pathogens that remarkably cause fungal infections ranging from superficial to fatal invasive disseminated infections. Fusarium species are notoriously resistant to the majority of antifungal agents. Objectives: Therefore, detailed studies regarding in vitro susceptibility are required and may lead to a better prognosis of severe infections. Methods: We evaluated 25 antifungal drugs in vitro against 282 clinical and environmental Fusarium isolates. Results: Fusarium species demonstrated high MICs/MECs values to the most commonly used antifungal drugs in clinical practice. The geometric mean (GM) MICs for luliconazole (0.004 μg/ml) and lanoconazole (0.012 μg/ml) were the lowest, followed by efinaconazole (0.98 μg/ml) and amphotericin B (1.04 μg/ml). Conclusions: Efinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis. © 2022 Wiley-VCH GmbH.
Other Related Docs
11. Fungal Keratitis in Iran: Risk Factors, Clinical Features, and Mycological Profile, Frontiers in Cellular and Infection Microbiology (2023)